[Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy].

Aim: We investigated the numbers and proportions of lymphocyte subsets in advanced ovarian cancer patients undergoing chemotherapy, so as to identify whether there is immune reconstitution after chemotherapy, and seek rational chemo-immunotherapy strategies in ovarian cancer treatment.

Methods: Blood samples from each ovarian cancer patient were obtained before (S(0)) and at day 5-7 (S(1)), day 12-14 (S(2)) and day 25-28 (S(3)) after chemotherapy in 13 patients. Flow cytometry technique was employed to analyse the numbers, proportions of CD3(+), CD4(+), CD8(+), CD4(+) CD25(+) Treg and memory-like phenotype lymphocyte subsets.

The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy.

Till now, little is known about the effects of chemotherapy on the immunity of cancer patients and the ideal timing ("window" period) for immunotherapy combined with chemotherapy. In this study, we addressed the immunogenicity of apoptotic ovarian cancer cells induced by paclitaxel and carboplatin, the immunologic aspects in ovarian cancer patients under chemotherapy, and the CTL response when CD8(+) T cells were stimulated with tumor antigen in the "window" period. The immunogenicity of apoptotic ovarian cancer cells was detected first.

[Effect of apoptotic ovarian cancer cells induced by paclitaxel-cisplatin on antigen presentation function of DC].

Aim: To explore wheather apoptotic ovarian cancer cells induced by paclitaxel-cisplatin could be cross-presented by antigen presenting cells and promote immune responses.

Methods: DCs were generated from peripheral blood monocytes in RPMI1640 supplemented with GM-CSF and IL-4. After 6 days' incubation, DCs were further co-cultured with either apoptotic HO8910 cell lines induced by paclitaxel-cisplatin or control cells for four hours.